Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Abnormal Proliferation02:23

Abnormal Proliferation

4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

11.3K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.3K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

5.7K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

<b>Taxonomy of the leafhopper genus <i>Limentinus</i> (Hemiptera: Cicadellidae: Coelidiinae) with description of three new species from Madagascar</b>.

Zootaxa·2026
Same author

From cross cancer transcriptomics to therapeutics: WGX-50 target hub genes in breast cancer and non-small cell lung carcinoma.

Computational biology and chemistry·2026
Same author

Safety and Efficacy of Plerixafor in Poor Mobilizers With Lymphoma: A Multicenter, Prospective, Single-Arm Study.

American journal of hematology·2026
Same author

LCP2 mediates SUV39H1-driven cellular senescence-related chemoresistance in natural killer/T-cell lymphoma.

Cell death & disease·2026
Same author

Effects of magnesium potassium sulfate on Tibetan sheep quality and its volatile and non-volatile metabolic substances.

Frontiers in nutrition·2026
Same author

Mutation Profiling, Efficacy Monitoring, and Prognosis Evaluation Using Circulating Tumor DNA in Peripheral T-Cell Lymphoma: A Prospective, Multicenter, Observational Study.

American journal of hematology·2026

相关实验视频

Updated: May 20, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

9.7K

默特克在异位表达,并影响扩散大B细胞淋巴瘤的生物功能.

Yan Li1,2, Cunzhen Shi1, Jiazhuo Wu1

  • 1Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Hematological oncology
|May 19, 2025
PubMed
概括

在扩散性大B细胞淋巴瘤 (DLBCL) 中,MerTK的表达很高. 抑制MerTK抑制DLBCL细胞的生长和进展,为这种侵袭性癌症提供了潜在的新精确治疗点.

关键词:
附录A1 附录A1 是一个在 MerTK 找 MerTK自自是自的过程.扩散的大B细胞淋巴瘤有针对性的治疗.

更多相关视频

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

12.0K
Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

2.7K

相关实验视频

Last Updated: May 20, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

9.7K
In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

12.0K
Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

2.7K

科学领域:

  • 在瘤学瘤学.
  • 分子生物学分子生物学
  • 癌症研究 癌症研究

背景情况:

  • 复发性/耐药性扩散性大B细胞淋巴瘤 (DLBCL) 缺乏有效的救援治疗方法.
  • 确定新的治疗点对于改善DLBCL患者的治疗结果至关重要.

研究的目的:

  • 研究MerTK (一种原瘤基因) 作为DLBCL治疗点的作用.
  • 在临床前DLBCL模型中评估MerTK抑制的疗效.

主要方法:

  • 免疫组织化学和西部涂抹,以评估DLBCL中的MerTK表达.
  • 在DLBCL细胞系和异种移植模型中使用shRNA进行MerTK淘汰.
  • 用UNC2025治疗,这是一个MerTK小分子抑制剂.
  • 转录组测序和KEGG通路分析.

主要成果:

  • 在DLBCL样本和细胞系中观察到异常高的MerTK表达.
  • 抑制MerTK (Knockdown或UNC2025) 降低了DLBCL细胞的增殖,诱导了细胞亡,并导致G2/M停止.
  • 抑制MerTK改变了基因表达,显著丰富了自途径,并上调了ANXA1.
  • 通过增加ANXA1表达,MerTK抑制抑制了自流.
  • 在DLBCL异种移植模型中,MerTK抑制在体内减少了瘤生长.

结论:

  • 在DLBCL中异位表达MerTK,并驱动瘤生长.
  • 向抑制MerTK在体外和体内表现出显著的抗瘤活性.
  • 在DLBCL中,MerTK是准确治疗的有希望的目标.